Dr. Inman on Immunotherapy Combinations in Bladder Cancer

Brant Inman, MD
Published: Monday, Nov 20, 2017



Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Patients with metastatic bladder cancer whose tumors did not respond to chemotherapy should consider using one of the checkpoint inhibitors, states Inman.

The other situation is for patients who are ineligible for cisplatin. According to Inman, if a patient cannot receive cisplatin, the best choice is to consider a checkpoint inhibitor.
 


Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Patients with metastatic bladder cancer whose tumors did not respond to chemotherapy should consider using one of the checkpoint inhibitors, states Inman.

The other situation is for patients who are ineligible for cisplatin. According to Inman, if a patient cannot receive cisplatin, the best choice is to consider a checkpoint inhibitor.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x